FDA 自 2026 年 10 月 16 日起接受 eCTD 4.0 版本提交
FDA Opens the Door to eCTD 4.0
FDA 自 2026 年 10 月 16 日起接受 eCTD 4.0 版本提交,包括最初以 v3.2.2 创建的申请。依据前向兼容安排,现有申请可继续推进并逐步过渡,v3.2.2 下提交的生命周期内容仍属于原申请。该通知面向 CDER 与 CBER,涵盖药品与生物制品,受联邦食品、药品和化妆品法案第 745A(a) 条电子提交要求约束的申报仍须按 FDA 数据标准目录当前支持的版本提交。
Since 16 October 2026, the U.S. Food and Drug Administration (FDA) has been accepting electronic Common Technical Document (eCTD) submissions in version 4.0, including for applications that were originally created under v3.2.2. Pharmaceutical companies do not have to abandon or restart ongoing procedures. Instead, they can make the transition step by step. Forward Compatibility as a BridgeUnder the forward compatibility arrangement, the FDA enables the move from eCTD v3.2.2 to version 4.0. Existing applications can continue while new content is already submitted in the updated format. Lifecycle content submitted under v3.2.2 remains part of the ongoing application. This is particularly useful for long-running approval procedures or extensive document holdings, since the entire dossier does not need to be restructured. Who Is AffectedThe notice is addressed to the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). It therefore covers both drug approvals and the biologics sector, including biotechnology-derived active substances and vaccines. The Requirement to Use the Current Version Still AppliesSubmissions subject to the electronic requirements of Section 745A(a) of the Federal Food, Drug, and Cosmetic Act must continue to be made in eCTD format and in the version currently supported by the FDA. Exceptions are only possible where provided by law or where the agency has granted a waiver. The FDA Data Standards Catalog states which version is currently accepted and should serve as the binding reference before every submission. Specifications and Public CommentThe FDA provides the technical specifications for eCTD v4.0 on its eCTD web page. Comments on the notice can be submitted at any time, either electronically or in writing, so that industry associations and companies can help shape how the rule is applied. What Regulatory Affairs Teams Should Do Now Identify ongoing v3.2.2 applications that are candidates for the transition Review the v4.0 technical specifications and integrate them into internal processes Check the FDA Data Standards Catalog for the currently accepted version before every submission Coordinate early with software vendors, document owners, and training needs
来源:ECA GMP News · gmp-compliance.org